TC Biopharm (Holdings) Plc (TCBP)
NASDAQ: TCBP · Real-Time Price · USD
0.660
+0.001 (0.15%)
At close: Dec 20, 2024, 4:00 PM
0.650
-0.010 (-1.52%)
After-hours: Dec 20, 2024, 7:51 PM EST
Company Description
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm (Holdings) Plc
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Feb 11, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Bryan Kobel |
Contact Details
Address: Maxim 1, 2 Parklands Way Motherwell, ML1 4WR United Kingdom | |
| Phone | 44 14 1433 7557 |
| Website | tcbiopharm.com |
Stock Details
| Ticker Symbol | TCBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| IPO Price | $4.25 |
| CIK Code | 0001872812 |
| CUSIP Number | 87807D103 |
| ISIN Number | US87807D4007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bryan Leland Kobel | Chief Executive Officer and Director |
| Martin Edward Thorp | Chief Financial Officer and Director |
| Christopher Camarra | Executive Vice President of Communications |
| Dr. Lauren Bor Ph.D. | Head of Commercial Development Division |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 6-K | Report of foreign issuer |
| Dec 16, 2024 | 424B5 | Filing |
| Dec 16, 2024 | 6-K | Report of foreign issuer |
| Dec 11, 2024 | EFFECT | Notice of Effectiveness |
| Nov 27, 2024 | F-3 | Filing |
| Nov 25, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | 6-K | Report of foreign issuer |
| Aug 30, 2024 | 6-K | Report of foreign issuer |
| Aug 29, 2024 | 424B4 | Prospectus |